The Effects of Botulinum Toxin on Oral Aperture in Patients With Scleroderma

NCT04523506 | Completed Early Phase 1 DMC FDA Drug

• 1 other identifier: STU-2020-0169
• Study Type: interventional
• Target: 17
• Locations: 1 country
• Sites: 1

Brief Summary

This study will evaluate the use of botulinum toxin for microstomia (also known as reduced oral aperture) in scleroderma patients. Botox is a neurotoxin that functions as a paralytic by preventing the release of acetylcholine to inhibit muscle contracture and decrease fibrosis by decreasing differentiation of fibroblasts to myofibroblasts, decreasing expression of collagen, and increasing expression of matrix metalloproteinase1-3. The study will include three arms: the temporomandibular joint (TMJ) group who will receive injections of Botox to the masseter, the perioral group who will receive injections of Botox around the lips, and a control group who will receive no treatment for ROA. Outcome measurements will include measurement of oral aperture size through measurement inter-labial distance and between the upper and lower lips and the inter-incisal distance, patient satisfaction via a Skindex16 survey, mouth disability via the Mouth Handicap in Systemic Sclerosis Scale (MHISS), and patient and physician satisfaction using the Visual Analogic Scale (VAS). The maximum number of subjects to be consented for this study is 30. The study is expected to last four months per subject from time of consent to last clinical evaluation. Conditions that may result in a subject exiting the study prior to completion date include non-compliance, withdrawal of consent, or safety concerns such as adverse events as a result of treatment.

Conditions

Scleroderma

Outcome Measures

Primary Outcomes (3)

• Changes in inter-labial distance

  Inter-labial distance is defined as the distance between the upper and lower lip at maximum mouth opening. Distance will be measured using digital calipers by the same operator

  This will be measured at baseline before treatment, 2 weeks after treatment, and 3 months after treatment.

• Changes interincisal distance

  Interincisal distance is defined by the didistance between upper and lower incisor at maximum mouth opening. Distance will be measured using digital calipers by the same operator

  This will be measured at baseline before treatment, 2 weeks after treatment, and 3 months after treatment.

• quality of life via a Skindex16 survey

  This is a patient quality of life survey using the skindex 16 survey form.

  This information will be collected at baseline before treatment, 2 weeks after treatment, and 3 months after treatment.

Secondary Outcomes (2)

• Changes in the inter-commissural distance

  This will be measured at baseline before treatment, 2 weeks after treatment, and 3 months after treatment.]

• Changes in the Mouth Handicap in Systemic Sclerosis Scale (MHISS)

  This will be measured at baseline before treatment, 2 weeks after treatment, and 3 months after treatment.]

Study Arms (2)

the temporomandibular joint (TMJ) group

EXPERIMENTAL

This study will evaluate the use of botulinum toxin for microstomia (reduced oral aperture) in scleroderma patients. The TMJ group will be injected with two units of Botox into four different injection points to each masseter (16 units of Botox total) at the initial visit. No additional Botox will be injected in subsequent visits. Botox is a neurotoxin that functions as a paralytic by preventing the release of acetylcholine to inhibit muscle contracture and decrease fibrosis by decreasing differentiation of fibroblasts to myofibroblasts, decreasing expression of collagen, and increasing expression of matrix metalloproteinase1

Biological: Botulinum toxin(Botox)

the perioral group

EXPERIMENTAL

Biological/Vaccine: Botulinum toxin(Botox) This study will evaluate the use of botulinum toxin for microstomia (reduced oral aperture) in scleroderma patients. The perioral group will be injected with two units of Botox into eight different injection points (16 units of Botox total) around the lips (in the orbicularis oris). Botox is a neurotoxin that functions as a paralytic by preventing the release of acetylcholine to inhibit muscle contracture and decrease fibrosis by decreasing differentiation of fibroblasts to myofibroblasts, decreasing expression of collagen, and increasing expression of matrix metalloproteinase1-3.

Biological: Botulinum toxin(Botox)

Interventions

Botulinum toxin(Botox) BIOLOGICAL

This study will evaluate the use of botulinum toxin for reduced oral aperture in scleroderma patients. Botox is a neurotoxin that functions as a paralytic by preventing the release of acetylcholine to inhibit muscle contracture and decrease fibrosis by decreasing differentiation of fibroblasts to myofibroblasts, decreasing expression of collagen, and increasing expression of matrix metalloproteinase.

the perioral group; the temporomandibular joint (TMJ) group

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Ddiagnosis of scleroderma (defined by the 2013 Classification Criteria for Systemic Sclerosis4,5)23,24 ) who also have microstomia (reduced oral aperture), defined as an inter-incisal distance less than 50 mm 6-7)m13,14 .
• Male and female subjects.
• English and non-English speakers.
• Subjects aged 18 years old to 65 years old will be considered

You may not qualify if:

• Patients under 18 years old will be excluded.
• Patients with a known history of a hypersensitivity to any Botox formulation or to any of the components in the formulation,
• Active skin infection at the proposed injection site.
• Concomitant neuromuscular disorder.
• Pregnant or lactating.
• Missing incisors.
• treatment with: cyclophosphamide, Ultraviolet A-1 therapy, or topical calcitriol..

Sponsors & Collaborators

• University of Texas Southwestern Medical Center: lead

Study Sites (1)

UT Southwestern Medical Center at Dallas - Dermatology Clinical Trials

Dallas, Texas, 75390-8802, United States

Location

MeSH Terms

Conditions

Scleroderma, Diffuse

Interventions

Botulinum Toxins, Type A

Condition Hierarchy (Ancestors)

Scleroderma, Systemic; Connective Tissue Diseases; Skin and Connective Tissue Diseases; Skin Diseases

Intervention Hierarchy (Ancestors)

Botulinum Toxins; Metalloendopeptidases; Endopeptidases; Peptide Hydrolases; Hydrolases; Enzymes; Enzymes and Coenzymes; Metalloproteases; Bacterial Proteins; Proteins; Amino Acids, Peptides, and Proteins; Bacterial Toxins; Toxins, Biological; Biological Factors

Study Officials

• Heather Goff, MD

  University of Texas Southwestern Medical Center

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: early phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Associate Professor

Study Record Dates

• First Submitted: July 19, 2020
• First Posted: August 21, 2020
• Study Start: May 8, 2020
• Primary Completion: April 22, 2021
• Study Completion: April 22, 2021
• Last Updated: April 28, 2021

Record last verified: 2021-04

Locations

US (1)